Paris-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI ...

Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution. Among 69 executives at ...

Dutch life sciences investor Forbion has raised €2.3 billion across two new funds to finance about 30 biotech companies, ...

Oxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that ...

Genmab and AbbVie's bispecific antibody epcoritamab, added to R-CHOP chemoimmunotherapy, cut the risk of progression or death by 51% in a Phase 3 trial in newly diagnosed diffuse large B-cell lymphoma ...

France’s WhiteLab Genomics has raised $26 million (€23 million) in Series B financing to expand experimental validation of ...

Australian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to ...

Genmab’s rinatabart sesutecan (Rina-S) delivered durable responses in a Phase 2 trial in platinum-resistant ovarian cancer, providing encouraging validation for the centerpiece of its $1.8 billion ...

Justyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization ...

Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an ...

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...

GSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, ...